Tagged with Strategy,

USA Jorge Alderete, president of ALK Americas, outlines the Danish mid-cap’s strategy in the challenging US market, including innovative market access initiatives, and how future models of patient-doctor interaction and medical distribution will look.   Affordability is key. We recently launched a specialty pharmacy network for our portfolio. This allows us…

Romania Mirela Iordan country manager of Pfizer Romania reveals some of her milestones, including integrating new acquisitions and setting up the first financial centre in Europe for Pfizer. She shares her insights on how the affiliate is working to maximise patients’ access to the latest innovations through patient assistance programs, early…

Mexico UCB’s Omar Lugo Aguirre outlines the company’s response to the COVID-19 pandemic in Mexico, countering stigmas around neurodegenerative and mental diseases, and the abundant opportunities that Mexico and the region carries for the firm.   The upcoming three years are crucial and UCB Mexico wants to play a role elevating…

China Alphamab Oncology and I-Mab Biopharma, two of China’s fastest-growing biotech firms, both bolstered by recent successful IPOs, are increasingly adapting their portfolio strategies to launch products on the large but challenging domestic Chinese market.   I-Mab: Observing Competitors and Staying Flexible I-Mab already has a fairly advanced China portfolio, with…

UAE Working non-stop to catch up with its footprint in other regions, Boston Scientific is investing heavily in the MENA markets. Tarek El Rahbani, managing director for the region, shares the company’s change in strategy, opting to have enhanced direct presence in the region. Moreover, he explains why Boston Scientific’s therapies…

Belgium Janssen in Belgium was founded in 1953 by Dr Paul Janssen, with only one thing in mind: saving people’s lives through the development of better medicines. In 1961, the company was acquired by Johnson & Johnson. Sonja Willems, managing director of Janssen Benelux, discusses the company’s response to the COVID-19…

Morocco Karim Lahlou of Moroccan pharma manufacturer Iberma discusses the firm’s evolution in recent years, the abundant opportunities for Iberma in the African market, and why strong international partnerships will help the company thrive in the future.   While we continue developing new business ideas, we are capitalizing on our stable…

Coronavirus With the global coronavirus pandemic still ongoing and teleworking having become the new normal, pharma executives from across the world are giving us their insights into how they are managing in the age of confinement to ensure continued employee welfare and the safe supply of medications to the patients and…

Morocco Salim El Guermai, CEO & head pharmacist of Galenica, a leading generics company in Morocco, presents the original mission of the company to provide high-quality affordable medicines to Moroccan patients by developing and manufacturing its own portfolio as an alternative to expensive imported drugs. El Guermai also shares his ambitions…

Mexico Americo Garcia oversees Latin American operations for Canadian generics player Apotex. He outlines the firm’s impressive growth in the region in recent years – expanding both in terms of portfolio and geographies -, gives his take on the proposed Mexican healthcare reforms, and explains how he has been able to…

Morocco Ali Besri, Pfizer Morocco GM and North Africa Lead reveals the importance of Morocco’s stability and assets allowing the country to be recognized internationally for its manufacturing investments and capabilities and highlights how Pfizer has capitalized on this with a footprint in the country for over half a century. Looking…

Belgium Anne-Laure Dreno, country president of AstraZeneca in Belgium, elaborates on the significant position Belgium and the local affiliate have for the group as a frontrunner in innovative areas such as creating value-based agreements for reimbursements, (clinical) research and development, and embracing the opportunities of patient data. Dreno also discusses her…